Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Nitric Oxide Donor on EPCs in CAD
NCT00090558Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nitroglycerin in coronary artery disease (CAD) (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Levels of endothelial precursor cells and Levels of nitric oxide. Started Aug 2004; status: completed.
02
Drugs
nitroglycerin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00090558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090558.